A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041) (CHORUS)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sotatercept in Adults With Combined Postcapillary and Precapillary Pulmonary Hypertension (CpcPH) and Heart Failure With Preserved Ejection Fraction (HFpEF)
Researchers are looking for other ways to treat people with combined postcapillary and precapillary pulmonary hypertension (CpcPH). This trial focuses on CpcPH that is related to heart failure with preserved ejection fraction (HFpEF). The goal of the study is to learn if participants who receive sotatercept live longer without their CpcPH-HFpEF getting worse than those who receive placebo.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Participants will have the option to continue or start treatment with sotatercept in the extension study, MK-7962-023 (NCT06814145), after completing the End of Treatment visit.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has clinical diagnosis of HF with preserved ejection fraction on optimized guideline-directed medical therapy
- Has CpcPH confirmed by right-heart catheterization
- Has NYHA FC II or III
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
-
Has a diagnosis of PH in World Health Organization Group 1, 3, 4, or 5
-
Has CV comorbidities:
- History of surgical or transcatheter correction of mitral or aortic stenosis or regurgitation within 12 months before Screening
- More than one valve replacement or repair (mechanical or bioprosthetic), or anticipated valve replacement or repair during the study
- History of serious, life-threatening, or hemodynamically significant arrhythmia, long corrected QT interval syndrome, or Brugada syndrome
- History of hypertrophic cardiomyopathy, infiltrative cardiomyopathy (including, but not limited to, cardiac amyloidosis), dilated cardiomyopathy, arrhythmogenic ventricular cardiomyopathy, or restrictive cardiomyopathy
-
History or evidence of chronic liver disease
-
Has a current diagnosis of end-stage renal disease
-
History of organ transplantation (except corneal transplant) or bone marrow transplantation ≤5 years before Screening or has a life expectancy of <12 months
-
History of malignancy ≤5 years before Screening, with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in situ, or ≤2 squamous cell carcinomas of the skin
-
Has any noncardiopulmonary condition or acute/chronic impairment(s) (other than dyspnea) that limits their ability to perform the 6-minute walk test
-
Has moderate or severe obstructive sleep apnea
-
Has a body mass index ≥50 kg/m^2
-
Has been treated with any approved pulmonary arterial hypertension-specific medications within 30 days of Randomization
-
Has background medication with the following agents: sodium-glucose cotransporter-2 inhibitor, renin-angiotensin-aldosterone system inhibitors, mineralocorticoid receptor antagonists, diuretics, and beta-blockers, that is not a stable dose for ≥30 days before Randomization
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Sotatercept
Participants will receive sotatercept 0.3 mg/kg via subcutaneous (SC) injection every 3 weeks until end of study (up to approximately 37 months). |
SC injection administered every 3 weeks.
Autres noms:
|
|
Comparateur placebo: Placebo
Participants will receive matching placebo via SC injection every 3 weeks until end of study (up to approximately 37 months). |
SC injection administered every 3 weeks. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to Clinical Worsening (TTCW)
Délai: Up to ~37 months
|
TTCW was defined as time to first occurrence of any of the following events: cardiovascular (CV) death, hospitalization due to worsening heart failure (HF) or pulmonary hypertension (PH), urgent visits due to worsening HF or PH, or deterioration in exercise capacity (≥15% decrease from baseline in 6-minute walk distance [6MWD], confirmed by 2 tests) due to worsening HF or PH. CV deaths are defined as any deaths with a primary CV cause, including acute myocardial infarction (MI), sudden cardiac death, HF, PH worsening, stroke, and other CV causes. |
Up to ~37 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to First Event of CV Death, Hospitalization Due to Worsening HF or PH, or Urgent Visit Due to Worsening HF or PH
Délai: Up to ~37 months
|
CV deaths are defined as any deaths with a primary CV cause, including acute MI, sudden cardiac death, HF, PH worsening, stroke, and other CV causes. The time to first event of CV death, hospitalization due to worsening HF or PH, or urgent visit due to worsening HF or PH will be presented. |
Up to ~37 months
|
|
Time to First Event of CV Death or Hospitalization Due to Worsening HF or PH
Délai: Up to ~37 months
|
CV deaths are defined as any deaths with a primary CV cause, including acute MI, sudden cardiac death, HF, PH worsening, stroke, and other CV causes. The time to first event of CV death or hospitalization due to worsening HF or PH will be presented. |
Up to ~37 months
|
|
Change From Baseline in 6MWD at Week 24
Délai: Baseline and Week 24
|
The 6MWD tests the distance walked in 6 minutes as an assessment of exercise capacity. The baseline value for 6MWD is the average of the 2 values collected during Screening. The change from baseline in 6MWD at Week 24 will be presented. |
Baseline and Week 24
|
|
Time to the Date of Death Due to Any Cause
Délai: Up to ~37 months
|
The time to date of death (all causes) will be presented. |
Up to ~37 months
|
|
Time to First Hospitalization Due to Worsening HF or PH
Délai: Up to ~37 months
|
The time to first hospitalization due to worsening HF or PH will be presented. |
Up to ~37 months
|
|
Time to First Urgent Visit Due to Worsening HF or PH
Délai: Up to ~37 months
|
The time to first urgent visit due to worsening HF or PH will be presented. |
Up to ~37 months
|
|
Percentage of Participants Maintaining and/or Improving New York Heart Association (NYHA) Functional Class (FC) at Week 24
Délai: Week 24
|
NYHA FC classifies the extent of heart failure. The percentage of participants maintaining and/or improving NYHA FC at Week 24 will be presented. |
Week 24
|
|
Change From Baseline in N-Terminal Pro-B-type Natriuretic Peptide (NT-proBNP) Levels at Week 24
Délai: Baseline and Week 24
|
NT-proBNP is a circulating biomarker that reflects myocardial stretch. The change from baseline in NT-proBNP levels at Week 24 will be presented. |
Baseline and Week 24
|
|
Number of Participants Who Experience One or More Adverse Events (AEs)
Délai: Up to ~37 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be presented. |
Up to ~37 months
|
|
Number of Participants Who Discontinue Study Intervention Due to an AE
Délai: Up to ~37 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be presented. |
Up to ~37 months
|
|
Time to CV Death
Délai: Up to ~37 months
|
CV deaths are defined as any deaths with a primary CV cause, including acute MI, sudden cardiac death, HF, PH worsening, stroke, and other CV causes. The time to CV death will be presented. |
Up to ~37 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Medical Director, Merck Sharp & Dohme LLC
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 7962-041
- 2025 (Subvention/contrat des NIH des États-Unis)
- MK-7962-041 (Autre identifiant: MSD)
- 2025-524634-25-00 (Identificateur de registre: EU CT)
- U1111-1331-4324 (Identificateur de registre: UTN)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .